Comparing BioAffinity Technologies (NASDAQ:BIAF) & MaxCyte (NASDAQ:MXCT)
Comparing BioAffinity Technologies (NASDAQ:BIAF) & MaxCyte (NASDAQ:MXCT)
MaxCyte (NASDAQ:MXCT – Get Rating) and bioAffinity Technologies (NASDAQ:BIAF – Get Rating) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, valuation, profitability, institutional ownership, dividends and analyst recommendations.
MaxCyte（納斯達克：MXCT-獲得評級）和生物親和力技術（NASDAQ：BIAF-獲得評級）都是小型股醫療公司，但哪個是更好的股票？我們將根據兩家公司的收益，風險，估值，盈利能力，機構所有權，股息和分析師建議的實力進行比較。
Analyst Ratings
分析師評級
This is a summary of recent ratings and recommmendations for MaxCyte and bioAffinity Technologies, as reported by MarketBeat.
這是最近對 MaxCyte 和生物親和技術的評級和建議的摘要，根據市場 Beat 的報告。
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| MaxCyte | 0 | 0 | 1 | 0 | 3.00 |
| bioAffinity Technologies | 0 | 0 | 0 | 0 | N/A |
| 銷售評級 | 保留評分 | 購買評級 | 強大的買入評級 | 評級分數 | |
| MaxCyte | 0 | 0 | 1 | 0 | 3.00 |
| 生物親和技術 | 0 | 0 | 0 | 0 | N/A |
MaxCyte currently has a consensus target price of $9.00, suggesting a potential upside of 63.93%. Given MaxCyte's higher probable upside, equities research analysts clearly believe MaxCyte is more favorable than bioAffinity Technologies.
目前共識目標價為 9.00 美元，表明潛在的上行空間為 63.93%。鑑於 MaxCyte 的可能上行空間較高，股票研究分析師清楚地認為，MaxCyte 比生物親和科技更有利。
Profitability
盈利
| Net Margins | Return on Equity | Return on Assets | |
| MaxCyte | -56.29% | -9.12% | -8.21% |
| bioAffinity Technologies | N/A | N/A | N/A |
| 淨利潤 | 權益回報率 | 資產回報率 | |
| MaxCyte | -56.29% | -9.12% | -8.21% |
| 生物親和技術 | N/A | N/A | N/A |
Valuation & Earnings
估值及收益
This table compares MaxCyte and bioAffinity Technologies' revenue, earnings per share (EPS) and valuation.
此表格比較了 MaxCyte 和生物親和技術的收入、每股收益 (EPS) 和估值。
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| MaxCyte | $33.89 million | 16.56 | -$19.08 million | ($0.23) | -23.87 |
| bioAffinity Technologies | N/A | N/A | -$6.33 million | N/A | N/A |
| 總收入 | 價格/銷售比率 | 淨收入 | 每股盈利 | 市盈比率 | |
| MaxCyte | 三億九千九百萬美元 | 16.56 | -一九千九百零八萬元 | (0.23 美元) | -23.87 |
| 生物親和技術 | N/A | N/A | -633 萬美元 | N/A | N/A |
bioAffinity Technologies has lower revenue, but higher earnings than MaxCyte.
生物親和科技的收入較低，但收益高於 MaxCyte。
Insider and Institutional Ownership
內幕和機構所有權
66.7% of MaxCyte shares are owned by institutional investors. Comparatively, 2.4% of bioAffinity Technologies shares are owned by institutional investors. 5.1% of MaxCyte shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
66.7% 的股份由機構投資者擁有。相比之下，2.4% 的生物親和科技股份由機構投資者擁有。5.1% 的 MaxCyte 股份由內部人士擁有。強大的機構所有權表明，對沖基金，捐贈基金和大型資金經理認為一家公司有望實現長期增長。
Summary
摘要
MaxCyte beats bioAffinity Technologies on 5 of the 9 factors compared between the two stocks.
MaxCyte 在 5 個因素中的 9 個因素比兩隻股票之間擊敗了生物親和技術。
About MaxCyte
關於億信
(Get Rating)
(取得評分)
MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company was incorporated in 1998 and is headquartered in Rockville, Maryland.
MaxCyte, Inc. 是一家全球性生命科學公司，致力於下一代細胞療法的發現、開發和商業化。其產品包括用於中小型轉染的靜態電解儀器 Expert ATX；用於蛋白質生產和藥物開發的流動電孔 Expert Stx，以及用於細胞分析的治療靶標的表達；Expert GtX 是用於治療應用中大規模轉染的流動電孔；以及用於非常大容量細胞工程的 Expert VlX。該公司還提供一次性處理組件（PA）來處理和電孔；以及支持 PA 的配件，例如電孔緩衝解決方案和軟件協議。該公司成立於 1998 年，總部位於馬里蘭州的羅克維爾。
About bioAffinity Technologies
關於生物親和技術
(Get Rating)
(取得評分)
bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat cancer at the cellular level. The company was founded in 2014 and is based in San Antonio, Texas.
BioAffinity 科技有限公司是一家生物技術公司，致力於開發非侵入性診斷測試和靶向癌症治療。該公司提供 CypAth 肺部診斷 test，用於及早發現肺癌。它還研究標靶療法以治療細胞水平的癌症。該公司成立於 2014 年，總部設在德克薩斯州聖安東尼奧。
Receive News & Ratings for MaxCyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MaxCyte and related companies with MarketBeat.com's FREE daily email newsletter.
接收最新消息及評分 -在下面輸入您的電子郵件地址，以通過 MarketBeat.com 的免費每日電子郵件通訊接收 Maxcyte 和相關公司的最新新聞和分析師評級的簡要每日摘要。
譯文內容由第三人軟體翻譯。